Skip to content
Home
Technology
The platform
Artificial Intelligence
BioClick
Nobel Prize heritage
Biosolution phases
Scientific papers
Patents
Pipeline
Pipeline overview
NCT: Over-the-Counter
NCT: Pharma
Cannabinoids
Santalene
Become a partner
Investors
Stock information
News
Email signup
Investor Relation Contacts
Governance
SEC Filings
Video
About
Leadership team
History
Jobs
Policies
Terms of Use
FCOI
Privacy Policy
Contact
News
Latest news
Media coverage
Investor news
News archive
Homepage
Open navigation
Home
Technology
The platform
Artificial Intelligence
BioClick
Nobel Prize heritage
Biosolution phases
Scientific papers
Patents
Pipeline
Pipeline overview
NCT: Over-the-Counter
NCT: Pharma
Cannabinoids
Santalene
Become a partner
Investors
Stock information
News
Email signup
Investor Relation Contacts
Governance
SEC Filings
Video
About
Leadership team
History
Jobs
Policies
Terms of Use
FCOI
Privacy Policy
Contact
News
Latest news
Media coverage
Investor news
News archive
January 30, 2026
-
investor
press clippings
yahoo! finance: eXoZymes demonstrates end-to-end biomanufacturability of NCT, from reaction to high-purity isolated product
Read the complete
coverage
here.